The science of aging: from cellular mechanisms to clinical potential

Aging is an unavoidable aspect of human biology. As with many biological processes, the inevitable changes which occur as we age are not driven by a single, underlying cause, but an accumulation of interconnected biological mechanisms. These result in not only the hallmark phenotypic signs of aging, but also an increase in disease prevalence for conditions such as neurodegenerative disorders and cardiovascular diseases. Given the significant impact that aging mechanisms can have on health, research in this field is rapidly growing.  In this article, we will look at some key ideas coming out of this field of research and explore why they may be so important.

Cellular and immune mechanisms of aging 

One biological phenomenon which contributes to the aging process is cellular senescence, in which somatic cells become permanently unable to enter the cell cycle yet remain metabolically active. Senescence is induced in response to a range of biological stresses, such as oxidative damage, or from normal biological mechanisms, such as repeated cell division, which results in gradual telomere shortening (1). As a result of an increasing prevalence of stresses and cell divisions, a progressive accumulation of senescent cells can be observed in tissues as an organism ages (2).

Initial evolutionary hypotheses suggested that cellular senescence serves protective functions such as for suppressing tumor cell proliferation and limiting tissue fibrosis (1, 3). Despite these benefits, there is growing evidence to suggest that this process is linked to many age-related conditions (3). For example, senescent cells secrete a range of senescence-associated secretory phenotype (SASP) factors which include growth factors, proteases, and inflammatory mediators (4). Whilst SASP signaling has short term benefits, long term exposure can cause chronic inflammation, tissue dysfunction and can contribute to degenerative conditions, such as Alzheimer’s or osteoarthritis, which are much more commonly observed in older populations (4, 5).

Chronic inflammation itself is also a recognized central driver of biological aging, contributing to progressive tissue dysfunction and increased disease susceptibility. This process, commonly known as inflammaging, affects the body on both a cellular and organ level. On a cellular level it can accelerate the senescence of hematopoietic stem cells (HSCs), causing a decline in immune function and promote the sustained release of inflammatory markers (6). At an organ level, chronic inflammation contributes to dysfunction across multiple systems. For example, increased cardiac remodeling in the heart which is associated with the development of cardiac disease, while in the brain inflammation can disrupt neural function, contributing to cognitive decline and impaired memory (7, 8). Beyond the cardiovascular and neurological systems, chronic inflammation has also been implicated in the pathogenesis of a wide range of age-associated diseases such as liver fibrosis, chronic obstructive pulmonary disease, and chronic kidney disease (6).

Alongside chronic inflammation, aging is also associated with profound remodeling of the immune system, a process known as immunosenescence (9). This phenomenon is not just a decline in immune function, but a widespread dysregulation. Alterations in the adaptive immune system disrupt normal immune cell populations causing increased vulnerability to infection and reduced vaccine efficacy. In contrast, components of the innate immune system are upregulated, further promoting sustained inflammatory signaling (6). In combination, these changes impair immune surveillance, increase the risk of cancer and degenerative conditions, and reinforce the chronic inflammatory environment which characterizes biological aging (9, 10).

Emerging approaches in aging biomarker research 

While cellular senescence, inflammaging, and immunosenescence are key features of biological aging, they represent only a subset of the mechanisms currently under investigation. As our understanding of aging biology advances, research efforts are increasingly focused on identifying measurable indicators that reflect these underlying processes and their contribution to age-related disease. In particular, inflammatory markers have emerged as valuable tools for monitoring disease risk, informing the development of targeted anti-inflammatory interventions, and improving patient stratification (8, 11). Assessing patterns and ratios of such markers may enable earlier identification of individuals at heightened risk, allowing for timely intervention and improved clinical outcomes. Furthermore, linking these biological signatures to modifiable lifestyle factors offers opportunities for preventative strategies aimed at reducing the burden of age-associated disease.

Current aging research increasingly adopts a multi-dimensional approach, recognizing that no single biomarker can adequately capture the complexity of biological aging. Instead, integrated biomarker profiles are being prioritized, allowing the multisystem and heterogeneous nature of aging biology to be more accurately reflected (12). This shift is particularly important for understanding how aging mechanisms intersect across tissues and disease contexts. In parallel, the growing use of longitudinal study designs is expected to play a key role in future research, enabling investigation of how genetic background, environmental exposures, and lifestyle factors influence the rate of biological aging and supporting the identification of early predictive biomarker panels (13).

Conclusion 

These advances highlight the significant translational and clinical potential of research into the biological mechanisms of aging. By targeting age-associated processes, there is an opportunity to efficiently intervene across multiple diseases rather than addressing them in isolation. Emerging therapeutic strategies, such as senolytics, aim to modify underlying drivers of age-related pathology, with the potential to delay or mitigate disease progression. Meanwhile, the development of robust biomarker profiles may enable earlier intervention, improved patient stratification, and more effective monitoring of therapeutic responses. As our understanding of biological aging continues to advance, it is becoming increasingly clear that targeting aging itself may be fundamental to improving health and longevity.

Abbexa offers a broad range of products designed to support research into cellular senescence, inflammation, immunosenescence, and aging-related disease pathways:

If you’re looking for something specific or alternative species, view all products or contact us for a custom solution for your research.

References: 

1. Regulski, M. J. (2017). Cellular Senescence: What, Why, and How. Wounds: a compendium of clinical research and practice, 29(6), 168–174. PMID: 28682291.
2. Kumar, A., & Thirumurugan, K. (2023). Understanding cellular senescence: pathways involved, therapeutics and longevity aiding. Cell cycle (Georgetown, Tex.), 22(20), 2324–2345. https://doi.org/10.1080/15384101.2023.2287929
3. Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019). Cellular Senescence: Aging, Cancer, and Injury. Physiological reviews, 99(2), 1047–1078. https://doi.org/10.1152/physrev.00020.2018
4. Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nature reviews. Molecular cell biology, 22(2), 75–95. https://doi.org/10.1038/s41580-020-00314-w
5. Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022). Cellular senescence: a key therapeutic target in aging and diseases. The Journal of clinical investigation, 132(15), e158450. https://doi.org/10.1172/JCI158450
6. Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023). Inflammation and aging: signaling pathways and intervention therapies. Signal transduction and targeted therapy, 8(1), 239. https://doi.org/10.1038/s41392-023-01502-8
7. Ferrucci, L., & Fabbri, E. (2018). Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nature reviews. Cardiology, 15(9), 505–522. https://doi.org/10.1038/s41569-018-0064-2
8. Mekhora, C., Lamport, D. J., & Spencer, J. P. E. (2024). An overview of the relationship between inflammation and cognitive function in humans, molecular pathways and the impact of nutraceuticals. Neurochemistry international, 181, 105900. https://doi.org/10.1016/j.neuint.2024.105900
9. Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., Cheng, Q., Luo, P., Zhang, Y., & Han, X. (2023). Immunosenescence: molecular mechanisms and diseases. Signal transduction and targeted therapy, 8(1), 200. https://doi.org/10.1038/s41392-023-01451-2
10. Campisi, J., Kapahi, P., Lithgow, G. J., Melov, S., Newman, J. C., & Verdin, E. (2019). From discoveries in ageing research to therapeutics for healthy ageing. Nature, 571(7764), 183–192. https://doi.org/10.1038/s41586-019-1365-2
11. Andonian, B. J., Hippensteel, J. A., Abuabara, K., Boyle, E. M., Colbert, J. F., Devinney, M. J., Faye, A. S., Kochar, B., Lee, J., Litke, R., Nair, D., Sattui, S. E., Sheshadri, A., Sherman, A. N., Singh, N., Zhang, Y., & LaHue, S. C. (2025). Inflammation and aging-related disease: A transdisciplinary inflammaging framework. GeroScience, 47(1), 515–542. https://doi.org/10.1007/s11357-024-01364-0
12. Moaddel, R., Ubaida-Mohien, C., Tanaka, T., Lyashkov, A., Basisty, N., Schilling, B., Semba, R. D., Franceschi, C., Gorospe, M., & Ferrucci, L. (2021). Proteomics in aging research: A roadmap to clinical, translational research. Aging cell, 20(4), e13325. https://doi.org/10.1111/acel.13325
13. Tao, X., Zhu, Z., Wang, L., Li, C., Sun, L., Wang, W., & Gong, W. (2024). Biomarkers of Aging and Relevant Evaluation Techniques: A Comprehensive Review. Aging and disease, 15(3), 977–1005. https://doi.org/10.14336/AD.2023.00808-1